35. Pemphigus Clinical trials / Disease details
Clinical trials : 99 / Drugs : 124 - (DrugBank : 36) / Drug target genes : 23 - Drug target pathways : 169
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | ChiCTR2100042024 | 2018-06-01 | 2021-01-12 | Direct immunofluorescence of Tzanck smears for the diagnosis of pemphigus vulgaris: a diagnostic test | Direct immunofluorescence of Tzanck smears for the diagnosis of pemphigus vulgaris: a diagnostic test | Pemphigus vulgaris | Gold Standard:Gold standard: meet the diagnostic criteria of pemphigus vulgaris of Japan Dermatology Association in 2014 and the diagnosis made by two experts. Diagnostic criteria: including clinical manifestations, histopathological examination and immunodiagnostic indicators.;Index test:Direct immunofluorescence of Tzanck smears; | Peking University stomatological hospital | NULL | Recruiting | Both | Target condition:38;Difficult condition:38 | China | |||
| 2 | ChiCTR2100042023 | 2018-06-01 | 2021-01-12 | Evaluation of salivary anti Dsg1 and Dsg3 antibodies in diagnosis and monitoring of pemphigus vulgaris | Evaluation of salivary anti Dsg1 and Dsg3 antibodies in diagnosis and monitoring of pemphigus vulgaris | Pemphigus vulgaris | Gold Standard:Gold standard: At the same time, it met the diagnostic criteria of pemphigus vulgaris of Japan Dermatology Association in 2014 and was confirmed by two experts. Diagnostic criteria: including clinical manifestations, histopathological examination and immunodiagnostic indicators.;Index test:Salivary Dsg1 and Dsg3 titer; | Peking University School and Hospital of Stomatology | NULL | Recruiting | Both | Target condition:38;Difficult condition:38 | China |